Cisplatin and Pemetrexed With Radiation Followed by Lobectomy

Inclusion Criteria:

Histologically and cytologically confirmed non-squamous NSCLC.
Resectable T3, and or N2 disease (T3N1, and resectable T1-3N2 multi-station non-bulky with no nodal station being more than 2 cm on preoperative workup, T4N0-1
Resectable T3 includes patients with a satellite lesion in the same lobe as the primary.
Male or Female, aged > or = 18 years and be able to give informed consent.
Tumor should be technically operable with a lobectomy, bilobectomy or a sleeve resection.
Patient should be medically operable
ECOG Performance Status 0 or 1.
Adequate bone marrow, hepatic and renal function assessed within 28 days
Signed informed consent.
Women of childbearing potential should have negative pregnancy test prior to enrollment to study.
Men with partners in the childbearing age group and women of childbearing potential must use effective contraception while on treatment and for 6 months thereafter.
The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of Pemetrexed.
The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol.
Patients must have a negative MRI or CT Scan of the brain.

Exclusion Criteria:

Patients who have had chemotherapy or radiation therapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
Patients may not be receiving any other investigational agents.
History of allergic reactions attributed to compounds or other agents used in study.
Pregnant or lactating women.
Male patients with female sexual partners in the reproductive age group who refuse to use effective methods of contraception will be excluded from the trial.
Patients with concurrent serious infections.
Patients with an unstable or serious concurrent medical condition are excluded.
Presence of third space fluid which cannot be controlled by drainage.
Weight loss > 10 percent from baseline weight.
HIV-positive patients on combination antiretroviral therapy are ineligible
Patients with hypercalcemia will be excluded.
Patients who require a pneumonectomy will be excluded.